Nomura Holdings Inc. Sells 1,651 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Nomura Holdings Inc. has decreased its stake in Thermo Fisher Scientific by 10.7%, resulting in ownership of 13,776 shares valued at $6,855,000.
• Various hedge funds have made modifications to their positions in Thermo Fisher, with 89.23% of the stock owned by institutional investors.
• Thermo Fisher Scientific recently reported earnings surpassing expectations, with a quarterly EPS of $5.36 and a revenue of $10.86 billion.

Nomura Holdings Inc. decreased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 10.7% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 13,776 shares of the medical research company's stock after selling 1,651 shares during the period. Nomura Holdings Inc.'s holdings in Thermo Fisher Scientific were worth $6,855,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Bernard Wealth Management Corp. bought a new position in Thermo Fisher Scientific in the 4th quarter valued at $25,000. Ameriflex Group Inc. purchased a new position in Thermo Fisher Scientific during the fourth quarter worth about $30,000. Keystone Global Partners LLC purchased a new stake in shares of Thermo Fisher Scientific in the 1st quarter valued at about $31,000. IMA Advisory Services Inc. bought a new stake in shares of Thermo Fisher Scientific during the 1st quarter valued at about $35,000. Finally, Smallwood Wealth Investment Management LLC bought a new position in shares of Thermo Fisher Scientific in the first quarter worth approximately $37,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 385 shares of the business's stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares of the company's stock, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders sold 29,666 shares of company stock valued at $13,982,763 in the last 90 days. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Trading Up 1.0%

TMO stock traded up $4.94 during trading on Thursday, hitting $489.49. 1,404,235 shares of the company traded hands, compared to its average volume of 1,629,226. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $627.88. The company has a 50-day moving average of $459.03 and a 200-day moving average of $453.64. The firm has a market capitalization of $184.84 billion, a PE ratio of 28.31, a P/E/G ratio of 2.59 and a beta of 0.75.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm had revenue of $10.86 billion for the quarter, compared to analysts' expectations of $10.68 billion. During the same quarter last year, the business earned $5.37 earnings per share. The business's revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 9.95%.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Evercore ISI dropped their target price on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. Scotiabank upgraded shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price for the company in a research report on Friday, July 11th. Barclays raised their price target on Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an "equal weight" rating in a research report on Thursday, July 24th. Wall Street Zen upgraded Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Saturday, August 30th. Finally, Wells Fargo & Company decreased their price objective on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a report on Thursday, July 24th. Sixteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $589.38.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.